Department of Chemical Physiology and Biochemistry, Oregon Health & Science University, Portland, OR 97239-3098, USA.
Center for Developmental Health, Knight Cardiovascular Institute, Oregon Health & Science University, Portland, OR 97239-3098, USA.
Endocrinology. 2023 Aug 28;164(10). doi: 10.1210/endocr/bqad129.
We previously demonstrated that treating fetal lambs on gestational day 62 with the long-acting gonadotrophin-releasing hormone (GnRH) antagonist degarelix (DG) suppresses pituitary-testicular function during midgestation. The objective of this study was to investigate whether impaired gonadotrophic drive during this fetal period has enduring effects on sexual differentiation and reproductive function in adult male sheep. We assessed the effects of prenatal administration of DG, with or without testosterone (T) replacement, on various sexually dimorphic behavioral traits in adult rams, including sexual partner preferences, as well as neuroendocrine responsiveness and testicular function. Our findings revealed that DG treatment had no effect on genital differentiation or somatic growth. There were some indications that DG treatment suppressed juvenile play behavior and adult sexual motivation; however, male-typical sexual differentiation of reproductive behavior, sexual partner preference, and gonadotropin feedback remained unaffected and appeared to be fully masculinized and defeminized. DG-treated rams showed an increased LH response to GnRH stimulation and a decreased T response to human chorionic gonadotropin stimulation, suggesting impaired Leydig cell function and reduced T feedback. Both effects were reversed by cotreatment with T propionate. DG treatment also suppressed the expression of CYP17 messenger RNA, a key enzyme for T biosynthesis. Despite the mild hypogonadism induced by DG treatment, ejaculate volume, sperm motility, and sperm morphology were not affected. In summary, these results suggest that blocking GnRH during midgestation does not have enduring effects on brain sexual differentiation but does negatively affect the testes' capacity to synthesize T.
我们之前的研究表明,在妊娠第 62 天对胎儿羔羊给予长效促性腺激素释放激素(GnRH)拮抗剂 Degarelix(DG)治疗可抑制中期妊娠时的垂体-睾丸功能。本研究的目的是探讨在这个胎儿期受损的促性腺激素驱动是否对成年雄性绵羊的性分化和生殖功能产生持久影响。我们评估了产前给予 DG,是否结合或不结合睾酮(T)替代治疗,对成年公羊各种性别二态性行为特征的影响,包括性伴侣偏好,以及神经内分泌反应和睾丸功能。我们的研究结果表明,DG 处理对生殖器官分化或体生长没有影响。有一些迹象表明,DG 处理抑制了幼年的玩耍行为和成年的性动机;然而,雄性典型的生殖行为、性伴侣偏好和促性腺激素反馈的性分化不受影响,似乎完全雄性化和去女性化。DG 处理的公羊对 GnRH 刺激的 LH 反应增加,对人绒毛膜促性腺激素刺激的 T 反应降低,表明黄体细胞功能受损,T 反馈减少。丙酸睾酮的联合治疗可逆转这两种作用。DG 处理还抑制了 CYP17 信使 RNA 的表达,CYP17 信使 RNA 是 T 生物合成的关键酶。尽管 DG 处理引起轻度的性腺功能减退,但精液量、精子活力和精子形态不受影响。总之,这些结果表明,在中期妊娠期间阻断 GnRH 不会对大脑的性分化产生持久影响,但会对睾丸合成 T 的能力产生负面影响。